What is the present valuation and projected CAGR of the infectious disease therapeutics market?
The infectious disease therapeutics market size has grown strongly in recent years. It will grow from $141.08 billion in 2024 to $151.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, increasing incidence of viral diseases, growing awareness about diagnosis, rising demand for efficient and quick diagnostic testing, growing demand for cost-effective generic drugs, growing prevalence of infectious diseases, growing importance of antimicrobial stewardship.
The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $196.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing investments, expansion of clinical trial studies, increasing number of clinical trials, increasing focus on infectious disease prevention, increasing awareness about early diagnosis, growing awareness and funding. Major trends in the forecast period include partnerships, product approvals, investments, and research and developments in therapeutics.
Get Your Free Sample of The Global Infectious Disease Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp
What are the top drivers to the rising demand in the infectious disease therapeutics market?
The rising prevalence of infectious diseases is expected to propel the growth of the infectious disease therapeutics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. The rising infectious diseases are due to several key factors such as climate change and environmental disruption, antimicrobial resistance, weakened immune systems, increasing interactions with animals, and ecological disturbances. Infectious disease therapeutics play a vital role in treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases within communities and across populations. For instance, in November 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, the United States recorded 8,331 tuberculosis (TB) cases, with an incidence rate of 2.5 per 100,000 people. This marks a 5.9% rise in the number of cases and a 5.5% increase in the incidence rate compared to 2021. Therefore, the rising prevalence of infectious diseases drives the infectious disease therapeutics market.
How is the infectious disease therapeutics market segmented?
The infectious disease therapeutics market covered in this report is segmented –
1) By Type: Drugs, Vaccines
2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases
3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users
Subsegments:
1) By Drugs – Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)
2) By Vaccines – Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines
Order your report now for swift delivery
Who are the top competitors in the infectious disease therapeutics market?
Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.
What significant trends should we anticipate in the infectious disease therapeutics market over the forecast period?
Major companies operating in the infectious disease therapeutics market are investing in infectious disease drugs to develop more effective treatments, combat antimicrobial resistance, expand their product portfolios, and address emerging infectious threats. These investments aim to improve patient outcomes, meet unmet medical needs, and contribute to global public health efforts to control and manage infectious diseases. For instance, in June 2022, GSK, a UK-based healthcare company invested £1 billion ($1.09 billion) to proactively address infectious diseases in lower-income countries. This initiative aims to enhance research and development efforts to combat diseases that disproportionately affect these regions. The disparity in health research funding and resources between high-income and low- and middle-income countries underscores the urgency for such proactive investments to improve population health equitably.
Which regional trends are influencing the infectious disease therapeutics market, and which area dominates the industry?
North America was the largest region in the infectious disease therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Infectious Disease Therapeutics Market Report 2025 Offer?
The infectious disease therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Infectious disease therapeutics refers to the various treatments and interventions aimed at combating illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. The goal of infectious disease therapeutics is to either eliminate the infectious agent from the body or to control its replication and spread, thereby alleviating symptoms, preventing complications, and ultimately promoting recovery.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15594
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
